Cargando…
Cardiac safety of indacaterol in healthy subjects: a randomized, multidose, placebo- and positive-controlled, parallel-group thorough QT study
BACKGROUND: Indacaterol is a novel once-daily ultra long-acting β(2)-agonist for the treatment of chronic obstructive pulmonary disease. It is known that β(2)-agonists, like other adrenergic compounds, can prolong the QT-interval. This thorough QT/QTc study (as per ICH E14 guideline) evaluated the e...
Autores principales: | Khindri, Sanjeev, Sabo, Ronald, Harris, Stuart, Woessner, Ralph, Jennings, Simon, Drollmann, Anton F |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116479/ https://www.ncbi.nlm.nih.gov/pubmed/21615886 http://dx.doi.org/10.1186/1471-2466-11-31 |
Ejemplares similares
-
Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers
por: Jiang, Ji, et al.
Publicado: (2014) -
No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects
por: Demmel, Valentin, et al.
Publicado: (2018) -
Dabigatran Does Not Prolong the QT Interval with Supratherapeutic Exposure: a Thorough QT Study in Healthy Subjects
por: Ring, Arne, et al.
Publicado: (2013) -
Revefenacin, a Long‐Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo‐ and Positive‐Controlled Thorough QT Study
por: Borin, Marie T., et al.
Publicado: (2019) -
Randomized, Controlled, Thorough QT/QTc Study Shows Absence of QT Prolongation with Luseogliflozin in Healthy Japanese Subjects
por: Kumagai, Yuji, et al.
Publicado: (2015)